UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications

J. C. Chang; E. H. Liu; C. N. Lee; Y. C. Lin; M. C. Yu; K. J. Bai; Hsiang Yin Chen

doi:10.5588/ijtld.11.0404

UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications

J. C. Chang, E. H. Liu, C. N. Lee, Y. C. Lin, M. C. Yu, K. J. Bai, Hsiang Yin Chen

Research output: Contribution to journal › Article › peer-review

31 Citations (Scopus)

Abstract

First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl- transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95%CI 1.085-177.056). These findings require confirmation. However, screening for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.

Original language	English
Pages (from-to)	376-378
Number of pages	3
Journal	International Journal of Tuberculosis and Lung Disease
Volume	16
Issue number	3
DOIs	https://doi.org/10.5588/ijtld.11.0404
Publication status	Published - Mar 1 2012

Keywords

ATDH
Anti-tuberculosis drug-induced hepatotoxicity
NAT2
UGT1A1

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5588/ijtld.11.0404

Cite this

@article{173f35ec08c44ff783dd2764378cdfdf,

title = "UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications",

abstract = "First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl- transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95%CI 1.085-177.056). These findings require confirmation. However, screening for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.",

keywords = "ATDH, Anti-tuberculosis drug-induced hepatotoxicity, NAT2, UGT1A1",

author = "Chang, {J. C.} and Liu, {E. H.} and Lee, {C. N.} and Lin, {Y. C.} and Yu, {M. C.} and Bai, {K. J.} and Chen, {Hsiang Yin}",

year = "2012",

month = mar,

day = "1",

doi = "10.5588/ijtld.11.0404",

language = "English",

volume = "16",

pages = "376--378",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union Against Tuberculosis and Lung Disease ",

number = "3",

}

TY - JOUR

T1 - UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications

AU - Chang, J. C.

AU - Liu, E. H.

AU - Lee, C. N.

AU - Lin, Y. C.

AU - Yu, M. C.

AU - Bai, K. J.

AU - Chen, Hsiang Yin

PY - 2012/3/1

Y1 - 2012/3/1

N2 - First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl- transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95%CI 1.085-177.056). These findings require confirmation. However, screening for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.

AB - First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl- transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95%CI 1.085-177.056). These findings require confirmation. However, screening for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.

KW - ATDH

KW - Anti-tuberculosis drug-induced hepatotoxicity

KW - NAT2

KW - UGT1A1

UR - http://www.scopus.com/inward/record.url?scp=84863172644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863172644&partnerID=8YFLogxK

U2 - 10.5588/ijtld.11.0404

DO - 10.5588/ijtld.11.0404

M3 - Article

C2 - 22230213

AN - SCOPUS:84863172644

SN - 1027-3719

VL - 16

SP - 376

EP - 378

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

IS - 3

ER -

UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this